Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.
about
Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative DisordersMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.Sex differences in behavior and striatal ascorbate release in the 140 CAG knock-in mouse model of Huntington's disease.Ascorbic acid and the brain: rationale for the use against cognitive decline.Altered Neuronal Dynamics in the Striatum on the Behavior of Huntingtin Interacting Protein 14 (HIP14) Knockout MiceSodium-dependent vitamin C transporter 2 (SVCT2) expression and activity in brain capillary endothelial cells after transient ischemia in miceTriterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's diseaseAltered neural and behavioral dynamics in Huntington's disease: an entropy conservation approach.Does vitamin C deficiency affect cognitive development and function?Up-regulation of GLT1 reverses the deficit in cortically evoked striatal ascorbate efflux in the R6/2 mouse model of Huntington's disease.Neural correlates of unpredictability in behavioral patterns of wild-type and R6/2 miceNovel therapeutic targets for Huntington's disease.The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.Early exposure to dynamic environments alters patterns of motor exploration throughout the lifespan.Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington's disease phenotype in the R6/2 mouseAltered information processing in the prefrontal cortex of Huntington's disease mouse models.Vitamin C function in the brain: vital role of the ascorbate transporter SVCT2.Corticostriatal dysfunction underlies diminished striatal ascorbate release in the R6/2 mouse model of Huntington's disease.Antiallodynic effects of vitamin C and vitamin E in chronic post-ischemia pain rat model.A failure in energy metabolism and antioxidant uptake precede symptoms of Huntington's disease in mice.High-dose of vitamin C supplementation reduces amyloid plaque burden and ameliorates pathological changes in the brain of 5XFAD mice.Energy deficit in Huntington disease: why it matters.Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes.Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy.Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium.Ascorbate prevents cell death from prolonged exposure to glutamate in an in vitro model of human dopaminergic neurons.Does Vitamin C Influence Neurodegenerative Diseases and Psychiatric Disorders?Dysregulation of corticostriatal ascorbate release and glutamate uptake in transgenic models of Huntington's disease.The glutamate aspartate transporter (GLAST) mediates L-glutamate-stimulated ascorbate-release via swelling-activated anion channels in cultured neonatal rodent astrocytes.N-acetylcysteine modulates glutamatergic dysfunction and depressive behavior in Huntington's disease.The effects of ascorbic acid on penicillin-induced epileptiform activity in rats.Combined Low-Intensity Exercise and Ascorbic Acid Attenuates Kainic Acid-Induced Seizure and Oxidative Stress in Mice.Neuroprotective Natural Molecules, From Food to Brain
P2860
Q26775096-5AC81144-0677-4B7A-9A79-AE6D2D044341Q27005950-0165DEDE-419A-4C18-B6B4-75835BBF55A1Q30452232-F8FC54EC-DCA5-443D-A51F-5B9E9AC48288Q30501273-5AA52EC2-2AFF-4F2C-AF4E-17037F5AA87BQ33570528-CF99C3E3-8B83-4557-9403-972F57AB4253Q33772223-3573E43B-AEF4-46CC-B95A-99E518A8B33BQ33828357-72976DB0-2E6E-4B61-930D-C0494DF34162Q34043950-105A8DF6-0E1D-4349-AC76-40B4367C1AD7Q34146513-77D7C1EE-8DAA-4743-97F2-C3219F2D278EQ34263572-A6A8E6A2-43C3-4F28-B55F-45E815405205Q35885971-6FD55B59-6CE0-420F-A790-A930F1651B28Q36164246-35CAF4E2-D983-4180-8396-806C99F29EB8Q36219680-725E21D2-08AA-40E2-8D10-3D048250ED74Q36358871-DF23016A-695D-41DC-B1A7-9433DA64B0BDQ36624426-6AE62BFF-DDCF-4F0A-A89C-1E5B5CCB5AADQ36713909-D509ED01-4358-4DA0-96D8-D53114ABE2F5Q37002862-5EC70151-4A5A-4750-B9EC-915917C84245Q37113535-E8BE121B-F613-4C21-83D8-CBD3DF514780Q37349826-FE5392A2-224E-4691-9760-BFB965BBBB76Q37399681-88D13CC3-75A2-4950-92E0-A0F557183F49Q37528334-6DC4BD91-6CAF-46E3-B30A-FB46274C9161Q37620654-E66A656A-9EBF-4598-8398-72B90ED4EA5FQ37834195-E806BA51-8582-4B72-B0EF-ADFE2D4E0942Q38035863-00D6C6EB-9EE5-4BCC-8007-C14CB1CC7057Q38086474-CBD76ED9-25BC-4677-B1B3-3CF1F13BFE8EQ38603960-B80725AA-BB1B-404C-A7B3-673CF5C6FA44Q39101398-C705183D-C0E7-4E1A-A611-134F058C997EQ39400501-6610F4E7-353C-4CA2-AD65-0D36769D0ACCQ39425339-FCC6D203-A24B-4391-A9B4-AAE7E06E3291Q44938207-1AF043A2-3220-4116-A20A-A96C23C27708Q45295137-4FCF4B47-1C78-4AB1-BFE8-5E8D3347D760Q48204211-B205536D-E320-4D44-96B4-8CE1C23F4AF4Q50904583-06AADED6-2817-48CE-A7FB-DD4247EDB573Q58573296-A14C37A2-D368-4E76-90F2-BD3FBC04514A
P2860
Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.
@en
Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.
@nl
type
label
Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.
@en
Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.
@nl
prefLabel
Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.
@en
Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.
@nl
P2093
P1433
P1476
Ascorbate treatment attenuates the Huntington behavioral phenotype in mice.
@en
P2093
Ann M Marseilles
George V Rebec
Kristin Collins
Scott J Barton
P304
P356
10.1097/00001756-200307010-00015
P577
2003-07-01T00:00:00Z